Nxera Pharma swings to JPY3.175 billion operating profit on milestone gains
AI Summary- Nxera Pharma reported third-quarter operational progress and nine-month consolidated results.
- Revenue reached JPY27.742 billion, up JPY5.894 billion from the prior corresponding period.
- The company submitted South Korea’s vamorolone application and signed an eight-market QUVIVIQ agreement.